Barclays’s Lipocine LPCN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$75.2K Buy
+9,412
New +$82K ﹤0.01% 4147
2025
Q4
Sell
-9,412
Closed -$26.8K 5498
2025
Q3
$26.8K Hold
9,412
﹤0.01% 4897
2025
Q2
$29.7K Buy
+9,412
New +$30.5K ﹤0.01% 4790
2021
Q4
Sell
-1,416
Closed -$26K 4494
2021
Q3
$26K Buy
1,416
+1,003
+243% +$22.1K ﹤0.01% 4317
2021
Q2
$10K Sell
413
-857
-67% -$20.2K ﹤0.01% 4637
2021
Q1
$33K Buy
+1,270
New +$36.6K ﹤0.01% 4284
2020
Q3
Sell
-459
Closed -$10K 5413
2020
Q2
$10K Buy
+459
New +$5.95K ﹤0.01% 5323
2020
Q1
Hold
0
6331
2019
Q4
Sell
-3
Closed -$77 6610
2019
Q3
$0 Buy
+3
New +$120 ﹤0.01% 6948
2019
Q1
Sell
-1,776
Closed -$39K 7191
2018
Q4
$39K Sell
1,776
-100
-5% -$2.32K ﹤0.01% 5597
2018
Q3
$44K Hold
1,876
﹤0.01% 6155
2018
Q2
$41K Sell
1,876
-477
-20% -$11.4K ﹤0.01% 5756
2018
Q1
$61K Buy
+2,353
New +$65.5K ﹤0.01% 5753
2017
Q3
Sell
-2,051
Closed -$140K 6956
2017
Q2
$140K Buy
2,051
+1,663
+429% +$108K ﹤0.01% 4662
2017
Q1
$25K Buy
388
+285
+277% +$18.5K ﹤0.01% 5704
2016
Q4
$7K Buy
103
+97
+1,617% +$6.14K ﹤0.01% 6029
2016
Q3
$0 Sell
6
-17
-74% -$1.05K ﹤0.01% 6709
2016
Q2
$1K Buy
+23
New +$3.56K ﹤0.01% 6121

Other funds holding LPCN

Barclays's LPCN Position: Q1 2026 in Review

Barclays opened a new position in Lipocine (LPCN) in Q1 2026: 9,412 shares worth $75.2K. The stake represents ﹤0.01% of the portfolio and ranks #4147 among its holdings. This is a return to the name: Barclays previously reported a position in LPCN as recently as Q3 2025.

Barclays first reported a position in LPCN in Q2 2016 and has held it in 17 quarters since. The position peaked at $140K in Q2 2017. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Barclays held 9,412 shares of Lipocine worth $75.2K as of Q1 2026.
  • Lipocine was a new Barclays position in Q1 2026.
  • Lipocine made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4147 holding.
  • Barclays first reported a position in Lipocine in Q2 2016 and has held it in 17 quarters since.
  • Barclays's Lipocine position peaked at $140K in Q2 2017.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.